12.01.09
Indication: Bone mineral density
Source: American Journal of Clinical Nutrition, Vol. 90, No. 5, 1433-1439, November 2009
Research: The objective of this study was to test the effect of soy isoflavone supplementation on bone health. The multi-center, randomized, double-blind, placebo-controlled, 24-month trial was conducted to assess the effects of daily supplementation with 80 mg or 120 mg of soy hypocotyl aglycone isoflavones plus calcium and vitamin D on bone changes in 403 postmenopausal women. Study subjects were tested annually and changes in whole-body and regional bone mineral density (BMD), bone mineral content (BMC) and T scores were assessed. Changes in serum biochemical markers of bone metabolism were also assessed.
Results: After study site, soy intake and pretreatment values were controlled for, subjects receiving a daily supplement with 120 mg soy isoflavones had a statistically significant smaller reduction in whole-body BMD than did the placebo group both at 1 year (P < 0.03) and at 2 years (P < 0.05) of treatment. Smaller decreases in whole-body BMD T score were observed among this group of women at 1 year (P < 0.03) but not at 2 years of treatment. When compared with the placebo, soy isoflavone supplementation had no effect on changes in regional BMD, BMC, T scores, or biochemical markers of bone metabolism. Researchers concluded that daily supplementation with 120 mg soy hypocotyl isoflavones reduces whole-body bone loss but does not slow bone loss at common fracture sites in healthy postmenopausal women.
Source: American Journal of Clinical Nutrition, Vol. 90, No. 5, 1433-1439, November 2009
Research: The objective of this study was to test the effect of soy isoflavone supplementation on bone health. The multi-center, randomized, double-blind, placebo-controlled, 24-month trial was conducted to assess the effects of daily supplementation with 80 mg or 120 mg of soy hypocotyl aglycone isoflavones plus calcium and vitamin D on bone changes in 403 postmenopausal women. Study subjects were tested annually and changes in whole-body and regional bone mineral density (BMD), bone mineral content (BMC) and T scores were assessed. Changes in serum biochemical markers of bone metabolism were also assessed.
Results: After study site, soy intake and pretreatment values were controlled for, subjects receiving a daily supplement with 120 mg soy isoflavones had a statistically significant smaller reduction in whole-body BMD than did the placebo group both at 1 year (P < 0.03) and at 2 years (P < 0.05) of treatment. Smaller decreases in whole-body BMD T score were observed among this group of women at 1 year (P < 0.03) but not at 2 years of treatment. When compared with the placebo, soy isoflavone supplementation had no effect on changes in regional BMD, BMC, T scores, or biochemical markers of bone metabolism. Researchers concluded that daily supplementation with 120 mg soy hypocotyl isoflavones reduces whole-body bone loss but does not slow bone loss at common fracture sites in healthy postmenopausal women.
